ライフサイエンスコーパス: immunocompromised

1 etting, affecting the critically ill and the immunocompromised.

2 cant cause of morbidity and mortality in the immunocompromised.

3 cluding the very young, the elderly, and the immunocompromised.

4 and solid organs, even when the animals were immunocompromised.

5 ts with HZ, 58.7% were females and 6.6% were immunocompromised.

6 ts with successful viral control who are not immunocompromised.

7 egalovirus replication, even when profoundly immunocompromised.

8 to vaccination, such as the elderly and the immunocompromised.

9 to vaccination, such as the elderly and the immunocompromised.

10 hematological malignancies and those who are immunocompromised.

11 ts a threat to infants, the elderly, and the immunocompromised.

12 fatal case of progressive encephalitis in an immunocompromised adult presenting at disease onset as b

13 IPD incidence had declined significantly in immunocompromised adults (IRR 0.57, 95% CI, .40-.82).

14 HCMV infection can cause severe disease in immunocompromised adults and infants infected in utero T

15 onjugate vaccine (PCV13) was recommended for immunocompromised adults in the United States and Canada

16 PCV13 vaccination of immunocompromised adults may substantially reduce the re

17 al virus causes lung infections in children, immunocompromised adults, and in the elderly.

18 spiratory tract infection in young children, immunocompromised adults, and the elderly.

19 emic areas, especially in young children and immunocompromised adults.

20 in sub-Saharan Africa is NTS in children and immunocompromised adults.

21 nic to humans, especially young children and immunocompromised adults.

22 mor-infiltrating leukocytes and renders them immunocompromised against tumor cells.

23 more recurrences and excluded those who were immunocompromised and aged 75 years or older.

24 transplant recipients are more likely to be immunocompromised and are predisposed to serious infecti

25 Relapsing disease is common among immunocompromised and asplenic individuals(3,4) and drug

26 egative, opportunistic pathogen that infects immunocompromised and cystic fibrosis patients.

27 estine and a major opportunistic pathogen in immunocompromised and elderly patients.

28 ignificant cause of disease and death in the immunocompromised and elderly.

29 Within this largely immunocompromised and hospitalized cohort, 535 patients

30 ultidrug-resistant infections, especially in immunocompromised and hospitalized patients.

31 eveloped melanoma brain metastasis models in immunocompromised and immunocompetent mice, and tested t

32 ave tested cutaneous infections in different immunocompromised and immunocompetent mouse strains.

33 inuation of antifungal therapy (71%) in both immunocompromised and immunocompetent patients.

34 nodules, consolidations, and cavity in both immunocompromised and immunocompetent patients.

35 es in the lungs in a model of corticosteroid immunocompromised and in Cxcr2 deficient mice.

36 ch causes life-threatening disease among the immunocompromised and is a significant source of congeni

37 In both immunocompromised and some immunocompetent people, EBV c

38 use of viral diarrhea in young children, the immunocompromised, and the elderly.

39 lish a persistent infection in mice, even in immunocompromised animals, rendered these murine models

40 were performed either in cell culture or in immunocompromised animals.

41 virus infection in 2 patients, 1 of whom was immunocompromised; both patients had known equine contac

42 However, animal studies and a study in immunocompromised children suggested that repeated vacci

43 er (95% confidence interval [CI], 8.7-15) in immunocompromised compared to immunocompetent persons; t

44 sion of cell-mediated immune responses under immunocompromised conditions may facilitate the establis

45 heir immune status: nonimmunocompromised and immunocompromised distributed into hematologic or solid

46 Among them, 305 (38%) were immunocompromised, distributed into solid tumors (122),

47 on virus was attenuated for dissemination in immunocompromised guinea pigs but elicited ELISA and neu

48 However, following experimental challenge of immunocompromised guinea pigs, r129 induced significant

49 substantially attenuated for replication in immunocompromised guinea pigs.

50 virus shedding were significantly higher in immunocompromised HEV-infected pigs.

51 high risk (children younger than 3 years or immunocompromised [HIV-infected]) or low risk (aged 3 ye

52 of infection and how this is altered in the immunocompromised host are key goals for comprehension o

53 Roseolovirus reactivation in an immunocompromised host can cause severe pathologies.

54 f the underlying mechanisms and safety in an immunocompromised host is limited due to lack of a suita

55 nslocation across the intestinal tract in an immunocompromised host is substantially reduced after ph

56 us infection is an emerging challenge in the immunocompromised host, in whom it may be asymptomatic o

57 In immunocompromised host, the virus can reactivate but rar

58 ergillosis is a lethal mold infection in the immunocompromised host.

59 thogenesis of pulmonary aspergillosis in the immunocompromised host.

60 s (HCMV) causes significant morbidity in the immunocompromised host.

61 nd disseminated diseases, particularly among immunocompromised hosts and critically ill adults as wel

62 Transplant recipients and other immunocompromised hosts are at particular risk for devel

63 nts with HSV meningitis rapidly improve, but immunocompromised hosts have more neurologic sequelae an

64 e importance of considering this organism in immunocompromised hosts presenting with severe infection

65 This study found viruses in immunocompromised hosts that are genetically distinct fr

66 P multocida is a rare cause of infections in immunocompromised hosts, epidemiologically linked to exp

67 cant morbidity, particularly in neonates and immunocompromised hosts, highlighting the need for novel

68 tant CD4(+) T cells do not induce colitis in immunocompromised hosts.

69 pathological picture when transplanted into immunocompromised hosts.

70 the immune system such as might be found in immunocompromised hosts.

71 sed by these organisms have been reported in immunocompromised hosts.

72 mmunocompetent hosts and invasive disease in immunocompromised hosts.

73 l disease during waterborne epidemics and in immunocompromised hosts.

74 e of chronic respiratory tract infections in immunocompromised hosts.

75 mic non-typhoidal Salmonella infection in an immunocompromised human patient resulted in genome degra

76 and the following cytokine storm.IMPORTANCE Immunocompromised human patients can develop severe, oft

77 nd remain highly sensitive to pegIFNalpha in immunocompromised humanized mice.

78 an emerging and frequently fatal pathogen of immunocompromised humans and which, along with the close

79 mportant opportunistic parasite pathogen for immunocompromised individuals and a common cause of diar

80 s the current vaccine is not recommended for immunocompromised individuals and its efficacy decreases

81 ght the potential risk of DTMUV infection in immunocompromised individuals and warrant studies on the

82 PML results when oligodendrocytes within immunocompromised individuals are infected with the huma

83 hominissuis is associated with infection of immunocompromised individuals as well as patients with c

84 st adaptation and demonstrates the role that immunocompromised individuals can play in this process.

85 Immunocompromised individuals comprised 28% of IPD.

86 fection is a significant clinical problem in immunocompromised individuals such as organ transplant r

87 r the morbidity and mortality of millions of immunocompromised individuals worldwide, yet drugs that

88 ract infections in infants, the elderly, and immunocompromised individuals worldwide.

89 iratory disease in infants, the elderly, and immunocompromised individuals worldwide.

90 ersons, significant pathology is observed in immunocompromised individuals, and chronic CMV infection

91 hea worldwide, especially among children and immunocompromised individuals, and no effective drug tre

92 nificant cause of morbidity and mortality in immunocompromised individuals, and the development of a

93 of severe respiratory disease among infants, immunocompromised individuals, and the elderly.

94 tics, particularly for chronic infections in immunocompromised individuals, but also a potential need

95 In debilitated and immunocompromised individuals, C. albicans may spread to

96 tly become a significant clinical problem in immunocompromised individuals, especially in solid-organ

97 nst VZV is available but not recommended for immunocompromised individuals, highlighting the need for

98 n Pneumocystis jirovecii causes pneumonia in immunocompromised individuals, including human immunodef

99 the causative agent of fatal malignancies of immunocompromised individuals, including Kaposi's sarcom

100 ction causes severe disease and mortality in immunocompromised individuals, including organ transplan

101 illosis and other fungal infections occur in immunocompromised individuals, including patients who re

102 tive agent of commonly fatal malignancies of immunocompromised individuals, including primary effusio

103 se significant morbidity and mortality among immunocompromised individuals, posing an urgent need for

104 hogen that causes severe clinical disease in immunocompromised individuals, such as organ transplant

105 ngitis, a significant source of mortality in immunocompromised individuals, typically human immunodef

106 a major cause of morbidity and mortality in immunocompromised individuals, with no approved therapie

107 ith particularly grave impact on infants and immunocompromised individuals.

108 is a life-threatening infection that affects immunocompromised individuals.

109 cause life-threatening fungal meningitis in immunocompromised individuals.

110 auses disseminated infections in fetuses and immunocompromised individuals.

111 ly enhance the immunogenicity of vaccines in immunocompromised individuals.

112 n herpesvirus-8 (HHV-8) and usually occur in immunocompromised individuals.

113 tory tract infection in infants, elderly and immunocompromised individuals.

114 eningitis, and gastroenteritis, primarily in immunocompromised individuals.

115 iral therapy, or change in the prevalence of immunocompromised individuals.

116 hat increases the morbidity and mortality of immunocompromised individuals.

117 r life-threatening infections in elderly and immunocompromised individuals.

118 lderly adults, pregnant women, newborns, and immunocompromised individuals.

119 of invasive pneumococcal disease (IPD) among immunocompromised individuals.

120 birth defects and causes severe infection in immunocompromised individuals.

121 of progressive multifocal encephalopathy in immunocompromised individuals.

122 y debilitating human diseases, especially in immunocompromised individuals.

123 g cause of infection-associated mortality in immunocompromised individuals.

124 that causes a severe neurological disease in immunocompromised individuals.

125 athogen that can cause serious infections in immunocompromised individuals.

126 reness in terms of therapeutic management of immunocompromised individuals.

127 ently fatal lung disease primarily affecting immunocompromised individuals.

128 pable of causing serious diseases, mainly in immunocompromised individuals.

129 s, causing particularly severe infections in immunocompromised individuals.

130 have increased due to the growing number of immunocompromised individuals.

131 so cause severe complications in elderly and immunocompromised individuals.

132 al pathogen that can cause severe disease in immunocompromised individuals.

133 galovirus (HCMV), a significant pathogen for immunocompromised individuals.

134 the most pathogenic in genetically modified immunocompromised mice [BALB scid and non-obese diabetic

135 osporidium infection in vitro and in vivo in immunocompromised mice and dramatically reduces oocyst s

136 NV-3 infection model with a human isolate in immunocompromised mice and is the first report of lethal

137 acute leukemias following transplantation in immunocompromised mice at a mean latency of 16 weeks.

138 with (125)I and intravenously injected into immunocompromised mice bearing corresponding xenografts.

139 rbon (PFC) emulsion ex vivo and infused into immunocompromised mice bearing subcutaneous human U87 gl

140 identifies drugs performing well not only in immunocompromised mice but also in the presence of spont

141 Furthermore, in vivo studies in immunocompromised mice demonstrate that MDA-MB-231 TS ce

142 The immunocompromised mice demonstrated prolonged virus shed

143 nce of serum from immunocompetent C57BL/6 or immunocompromised mice lacking IgM antibodies (Rag 2(-/-

144 DeltaNLS lacks neurovirulence even in highly immunocompromised mice lacking the IFN-alpha/beta recept

145 atopoietic progenitor cells xenografted into immunocompromised mice that express human myeloid cell g

146 Here we transplant T cells into immunocompromised mice to mimic ART-induced T-cell expan

147 es, human scalp skin can be xenografted onto immunocompromised mice to study human HF cycling and man

148 Through use of immunocompromised mice with transgenic expression of hum

149 ts with undetectable plasma viral loads into immunocompromised mice would result in viral amplificati

150 ted hBTSCs were equally able to engraft into immunocompromised mice yielding cells with human-specifi

151 When grown in immunocompromised mice, both cell lines exhibited cell-t

152 acked the ability to engraft successfully in immunocompromised mice, but IDH1 overexpression in these

153 on-specific organoids were transplanted into immunocompromised mice, duodenum-like organoids and ileu

154 opulation amplification is rapidly lethal in immunocompromised mice, it is controlled in immunocompet

155 ulation and serial reconstitution ability in immunocompromised mice.

156 ned organized following s.c. implantation in immunocompromised mice.

157 wild-type-like fitness in cultured cells and immunocompromised mice.

158 and function following transplantation into immunocompromised mice.

159 ow, and reconstitute human haematopoiesis in immunocompromised mice.

160 m tumors in subcutaneous xenograft assays in immunocompromised mice.

161 hat have been passaged as xenotransplants in immunocompromised mice.

162 ither subcutaneously or intraperitoneally in immunocompromised mice.

163 anoikis, and CBS-dependent tumorigenesis in immunocompromised mice.

164 fer protection against M. avium infection in immunocompromised mice.

165 n vivo, forming large and invasive tumors in immunocompromised mice.

166 transplantation under the kidney capsule of immunocompromised mice.

167 eactivation of chronic infection in severely immunocompromised mice.

168 lated from the serum of chronically infected immunocompromised mice.

169 potent reduction in intestinal infection of immunocompromised mice.

170 ng passenger loads into human cell lines and immunocompromised mouse models.

171 on to HAdV-5 transduction in the presence of immunocompromised mouse serum.

172 sal infection in several immunocompetent and immunocompromised mouse strains.

173 In summary, we have established immunocompromised murine models for influenza B virus in

174 Here, we developed an immunocompromised murine models for influenza B virus in

175 erived tumor cells to be nearly abolished in immunocompromised nude mice.

176 nd mortality, especially in hospitalized and immunocompromised or critically ill patients.

177 they were performed on tissue sections from immunocompromised or germ-free hosts, chronically infect

178 However, infection in immunocompromised or immunosuppressed individuals can re

179 cause significant morbidity and mortality in immunocompromised or naive individuals, particularly tra

180 in immunocompetent syngeneic mice but not in immunocompromised or Treg cell-depleted mice.

181 Here, we describe the fatality of an immunocompromised patient who received the varicella vac

182 We describe the case of an immunocompromised patient, positive for influenza A viru

183 fections, chronic infections may occur among immunocompromised patients (e.g., transplant recipients

184 esponses have been extensively documented in immunocompromised patients and during in utero acquisiti

185 associated with life-threatening diseases in immunocompromised patients and in otherwise healthy indi

186 fungal infection that predominantly affects immunocompromised patients and is uniformly fatal if lef

187 infection is increasingly being reported in immunocompromised patients and particularly organ transp

188 ether these new strains are of risk to other immunocompromised patients and the general population.

189 sent an emerging problem during treatment of immunocompromised patients and those hospitalized with s

190 pre-existing pulmonary lesions, and severely immunocompromised patients are susceptible to develop in

191 tococcus neoformans, a yeast that can affect immunocompromised patients as an opportunistic pathogen.

192 bacteria across the intestinal epithelium of immunocompromised patients can lead to bacteremia and li

193 rugs for the treatment of HAdV infections in immunocompromised patients continues to be a challenging

194 Nonsymptomatic immunocompromised patients had similar VZV-specific immu

195 The VOS is highly suggestive for IPA in immunocompromised patients in general.

196 in immunocompetent individuals, their use in immunocompromised patients is complicated by the develop

197 major challenge in treating toxoplasmosis in immunocompromised patients is lack of therapeutic agents

198 pathogens represent a significant threat to immunocompromised patients or individuals with traumatic

199 tinal lymphatic transport of cannabinoids in immunocompromised patients requires caution.

200 microbial therapy for babesiosis in severely immunocompromised patients should be extended to 6 weeks

201 Immunocompromised patients showed moderate to good serol

202 biota, as well as the unique epidemiology of immunocompromised patients that renders them a particula

203 Immunocompromised patients were less likely to have EBV

204 The conditions of immunocompromised patients were mimicked by treating pig

205 Sixty-five fecal samples from 16 immunocompromised patients were retrospectively selected

206 Our study included immunocompromised patients who received 1 or 2 hepatitis

207 In immunocompromised patients with acute respiratory failur

208 minimum of 6 weeks of antibiotics for highly immunocompromised patients with babesiosis, with no para

209 ificantly improved with antiviral therapy in immunocompromised patients with herpes meningitis (P < .

210 of noninvasive ventilation in critically ill immunocompromised patients with hypoxemic acute respirat

211 The objective was to assess outcomes of immunocompromised patients with hypoxemic acute respirat

212 In immunocompromised patients with hypoxemic acute respirat

213 Critically ill immunocompromised patients with hypoxemic acute respirat

214 deep-sequence longitudinal samples from four immunocompromised patients with long-term H3N2 influenza

215 CTPA studies of 78 consecutive immunocompromised patients with proven/probable IPA were

216 asibility of developing an immunotherapy for immunocompromised patients with uncontrolled infections.

217 Practice-compliant manufacturing process, in immunocompromised patients with uncontrolled infections.

218 The indication for prophylaxis in immunocompromised patients without HIV is less well defi

219 45 immunocompromised patients without IPA served as a contr

220 esting to specific groups of patients (e.g., immunocompromised patients), or providing education to e

221 Of 85 immunocompromised patients, 65 used immunosuppressive dr

222 and complement fixation, is not impaired in immunocompromised patients, and permits highly reproduci

223 HAstV 1-8, are neuropathic, particularly in immunocompromised patients, and should be considered in

224 use of viral diarrhea worldwide in children, immunocompromised patients, and the elderly.

225 ve vaccine efficacy in infants, the elderly, immunocompromised patients, as well as healthy adults.

226 Varicella can be lethal to immunocompromised patients, babies, HIV patients and oth

227 ssociated with a variety of complications in immunocompromised patients, but no studies have systemat

228 or relevance due to the increased numbers of immunocompromised patients, frequently delayed diagnosis

229 For some SCCs, particularly those in immunocompromised patients, human papillomavirus (HPV) m

230 sent potentially important considerations in immunocompromised patients, in particular in organ trans

231 decreased sensitivity may be problematic for immunocompromised patients, in whom low levels of HAdV i

232 illus fumigatus, which is a major threat for immunocompromised patients, including allogeneic hematop

233 zed trial conducted among 374 critically ill immunocompromised patients, of whom 317 (84.7%) were rec

234 a major cause of morbidity and mortality in immunocompromised patients, particularly those infected

235 elderly men, pregnant women, young children, immunocompromised patients, patients with preexisting li

236 s well as the threats of viral infections in immunocompromised patients, underline our efforts to cha

237 s the spectrum of EBV(+)diseases, even among immunocompromised patients, with plasma specimens more i

238 bolic or malignant diseases, particularly in immunocompromised patients.

239 sponsible for deadly, invasive infections in immunocompromised patients.

240 e of serious human infections, especially in immunocompromised patients.

241 in a larger cohort including non-hematologic immunocompromised patients.

242 uences, infection can be life threatening in immunocompromised patients.

243 s, particularly affecting critically ill and immunocompromised patients.

244 s that causes severe disease in newborns and immunocompromised patients.

245 tunistic pathogens and can pose a threat for immunocompromised patients.

246 y prevalent health problem, especially among immunocompromised patients.

247 rus JC virus, which typically occurs only in immunocompromised patients.

248 enotype 3 may result in chronic hepatitis in immunocompromised patients.

249 iratory disease in infants, the elderly, and immunocompromised patients.

250 fe-threatening syndrome that often occurs in immunocompromised patients.

251 oformans is a significant fungal pathogen of immunocompromised patients.

252 d to life-threatening meningoencephalitis in immunocompromised patients.

253 for the treatment of chronic hepatitis E in immunocompromised patients.

254 viduals and for a severe invasive disease in immunocompromised patients.

255 f infectious diseases in transplantation and immunocompromised patients.

256 encephalitis is particularly challenging in immunocompromised patients.

257 enza vaccine immunogenicity is suboptimal in immunocompromised patients.

258 ing cutaneous and subcutaneous infections in immunocompromised patients.

259 pneumonia (Pneumocystis pneumonia [PcP]) in immunocompromised patients.

260 nocardiosis and compared immunocompetent and immunocompromised patients.

261 causes potentially fatal bacteremia in some immunocompromised patients.

262 nd a significant health risk, especially for immunocompromised patients.

263 VZV-infected brains obtained at autopsy from immunocompromised patients.

264 and disappointing results in the elderly and immunocompromised patients.

265 tly become a significant clinical problem in immunocompromised patients.

266 be an alternative approach, particularly for immunocompromised patients.

267 merged as a cause of chronic hepatitis among immunocompromised patients.

268 s (IPA) is one of the major complications in immunocompromised patients.

269 g life-threatening invasive aspergillosis in immunocompromised patients.

270 istent infection can cause severe disease in immunocompromised people and is epidemiologically linked

271 nia in foals less than six months in age and immunocompromised people.

272 es had decreased by 90% (95% CI, 77%-96%) in immunocompromised persons of all ages.

273 ed for MSM, people living with HIV/AIDS, and immunocompromised persons through age 26 years.

274 In 2011/2012, 37% of isolates causing IPD in immunocompromised persons were PCV13 serotypes and 27% w

275 in the general population or for therapy in immunocompromised persons with persistent infection is l

276 2115/7604 (28%) episodes of IPD occurred in immunocompromised persons.

277 , it can be life threatening in neonates and immunocompromised persons.

278 ific CD4(+) T-cell responses were reduced in immunocompromised pigs during the acute phase of infecti

279 Immunocompromised pigs infected with HEV progressed to c

280 Results showed that HEV infection of immunocompromised pigs reduced the serum levels of Th1 c

281 ngal pathogen that predominantly affects the immunocompromised population and causes 600,000 deaths/y

282 study whether prolonged shedders within the immunocompromised population could be a reservoir for ne

283 human pathogen, causing serious diseases in immunocompromised populations and congenially infected n

284 incidence and case fatality were measured in immunocompromised populations over time, and the contrib

285 se of disease and death in the pediatric and immunocompromised populations, and its impact on the hos

286 being a major health issue in the aging and immunocompromised populations.

287 ficacies in young children, the elderly, and immunocompromised populations.

288 V7 were associated with reductions in IPD in immunocompromised populations.

289 spiratory disease in pediatric, elderly, and immunocompromised populations.

290 and may fail to provide adequate immunity in immunocompromised populations.

291 ns and are especially severe in neonatal and immunocompromised populations.

292 ajor health problem worldwide, especially in immunocompromised populations.

293 people each year with lethal consequences in immunocompromised populations.

294 Only age and immunocompromised state remained significant predictors

295 ficiency in naive CD4(+) T cells leads to an immunocompromised state that both promotes chronic toxop

296 g a ventilator-associated condition included immunocompromised status (odds ratio, 2.90; 95% CI, 1.57

297 Higher age, immunocompromised status, and higher Sequential Organ Fa

298 Patients with an immunocompromised system are at high risk of infections

299 of liver disease and hepatocarcinogenesis in immunocompromised versus immunocompetent Fah-deficient m

300 phenotype not only in wild-type but also in immunocompromised zebrafish embryos lacking either macro